BioInvent International マネジメント

マネジメント基準チェック /34

BioInvent Internationalの CEO はMartin Welschofで、 Sep2018年に任命され、の在任期間は 6.17年です。の年間総報酬はSEK 5.17Mで、 55.5%給与と44.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.034%を直接所有しており、その価値はSEK 990.07K 。経営陣と取締役会の平均在任期間はそれぞれ5年と6.8年です。

主要情報

Martin Welschof

最高経営責任者

SEK 5.2m

報酬総額

CEO給与比率	55.5%
CEO在任期間	6.2yrs
CEOの所有権	0.03%
経営陣の平均在職期間	5yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

BioInvent International の収益と比較して、Martin Welschof の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 410m
Jun 30 2024	n/a	n/a	-SEK 383m
Mar 31 2024	n/a	n/a	-SEK 335m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 330m
Sep 30 2023	n/a	n/a	-SEK 311m
Jun 30 2023	n/a	n/a	-SEK 304m
Mar 31 2023	n/a	n/a	-SEK 48m
Dec 31 2022	SEK 5m	SEK 3m	-SEK 43m
Sep 30 2022	n/a	n/a	-SEK 43m
Jun 30 2022	n/a	n/a	-SEK 42m
Mar 31 2022	n/a	n/a	-SEK 266m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 278m
Sep 30 2021	n/a	n/a	-SEK 171m
Jun 30 2021	n/a	n/a	-SEK 141m
Mar 31 2021	n/a	n/a	-SEK 123m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 76m
Sep 30 2020	n/a	n/a	-SEK 146m
Jun 30 2020	n/a	n/a	-SEK 150m
Mar 31 2020	n/a	n/a	-SEK 144m
Dec 31 2019	SEK 4m	SEK 2m	-SEK 139m
Sep 30 2019	n/a	n/a	-SEK 130m
Jun 30 2019	n/a	n/a	-SEK 116m
Mar 31 2019	n/a	n/a	-SEK 126m
Dec 31 2018	SEK 3m	SEK 800k	-SEK 123m

報酬と市場: Martinの総報酬 ($USD 472.94K ) は、 UK市場 ($USD 734.17K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Martinの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Martin Welschof (63 yo)

6.2yrs

在職期間

SEK 5,167,000

報酬

Dr. Martin Welschof, Ph D had been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018.He i...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Martin Welschof	President & CEO	6.2yrs	SEK 5.17m	0.034% SEK 990.1k
Stefan Ericsson	Chief Financial Officer	8.8yrs	データなし	0.012% SEK 353.7k
Marie Moores	Chief Operating Officer	2.8yrs	データなし	データなし
Kristoffer Hansson	Senior Vice President of Technical Operations	8.2yrs	データなし	0.034% SEK 985.7k
Björn Frendéus	Chief Scientific Officer	no data	SEK 2.35m	0.035% SEK 1.0m
Cecilia Hofvander	Senior Director of Investor Relations	3.8yrs	データなし	データなし
Andres McAllister	Chief Medical Officer	7.8yrs	データなし	0.0046% SEK 132.9k
Ingrid Teige	Head of Preclinical Research	no data	データなし	データなし
Sylvie Ryckebusch	Chief Business Officer	2.4yrs	データなし	0.035% SEK 1.0m
Ingunn Lindvig	Senior Vice President of Regulatory Affairs	1.4yrs	データなし	データなし

5.0yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: 0H22の経営陣は経験豊富であると考えられます ( 5年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Bernd Seizinger	Independent Director	6.8yrs	SEK 595.00k	0.10% SEK 2.9m
Leonard Kruimer	Independent Chairman of the Board	6.8yrs	SEK 782.00k	0.051% SEK 1.5m
Thomas Hecht	Independent Director	4.3yrs	SEK 510.00k	データなし
Vincent Ossipow	Independent Director	3.6yrs	SEK 475.00k	データなし
Alexander Rudensky	Member of Scientific Advisory Board	7.8yrs	データなし	データなし
Alexander Maximiliaan Eggermont	Member of Scientific Advisory Board	3.1yrs	データなし	データなし
Falk Nimmerjahn	Member of Scientific Advisory Board	7.8yrs	データなし	データなし
Vessela Alexieva	Employee Representative Director	no data	データなし	0.0014% SEK 41.3k
Kristoffer Bissessar	Independent Director	4.5yrs	SEK 520.00k	0.044% SEK 1.3m
Rienk Offringa	Member of Scientific Advisory Board	7.8yrs	データなし	データなし
Mark Cragg	Member of Scientific Advisory Board	no data	データなし	データなし
Stephen Beers	Member of Scientific Advisory Board	no data	データなし	データなし

6.8yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: 0H22の取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

BioInvent International マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Insufficient new directors

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

Independent Director recently bought kr603k worth of stock

Independent Director recently bought kr238k worth of stock

Independent Chairman of the Board recently bought kr127k worth of stock

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

Recent updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Third quarter 2024 earnings released: kr1.48 loss per share (vs kr1.08 loss in 3Q 2023)

Insufficient new directors

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

New major risk - Share price stability

Second quarter 2024 earnings released: kr2.09 loss per share (vs kr1.34 loss in 2Q 2023)

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

New minor risk - Share price stability

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

First quarter 2024 earnings released: kr1.18 loss per share (vs kr1.12 loss in 1Q 2023)

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

Full year 2023 earnings released: kr5.02 loss per share (vs kr0.69 loss in FY 2022)

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

New minor risk - Market cap size

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Third quarter 2023 earnings released: kr1.08 loss per share (vs kr1.00 loss in 3Q 2022)

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

Independent Director recently bought kr603k worth of stock

Second quarter 2023 earnings released: kr1.34 loss per share (vs kr2.86 profit in 2Q 2022)

New minor risk - Market cap size

Independent Director recently bought kr238k worth of stock

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

Independent Chairman of the Board recently bought kr127k worth of stock

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

High number of new directors

Forecast to breakeven in 2025

Full year 2022 earnings released

Forecast to breakeven in 2025

Forecast to breakeven in 2025

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

Third quarter 2022 earnings released: kr1.00 loss per share (vs kr1.07 loss in 3Q 2021)

Forecast to breakeven in 2024

BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023

BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

Forecast to breakeven in 2024

Second quarter 2022 earnings released: EPS: kr2.86 (vs kr0.98 loss in 2Q 2021)

BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors

Bioinvent International Resolves to Elect Natalie Berner and Nanna Lüneborg as New Board Members

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Bioinvent International AB (Publ) Appoints Sylvie Ryckebusch as Chief Business Officer

Forecast to breakeven in 2023

First quarter 2022 earnings released: kr1.16 loss per share (vs kr1.94 loss in 1Q 2021)

Full year 2021 earnings released: kr5.14 loss per share (vs kr2.66 loss in FY 2020)

President & CEO recently bought kr249k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioInvent International AB (publ) to Report Q3, 2022 Results on Oct 27, 2022

Independent Director recently bought kr399k worth of stock

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

BioInvent International AB (publ)(OM:BINV) dropped from OMX Nordic Small Cap Index

Independent Director recently bought kr762k worth of stock

BioInvent International AB (publ) Announces Positive Early Data from Ongoing Solid Cancer Trial of BI-1206 in Combination with Pembrolizumab

Bioinvent International Announces Updated Positive Interim Top-Line Data from Its Novel Anti-FcyRIIB Antibody Bi-1206

マネジメント基準チェック /34